Pasithea Therapeutics Reports $5.3 Million Net Loss for Q2 2026, Driven by Rising R&D Expenses

Pasithea Therapeutics Corp. reported a net loss of $5.3 million for the three months ended June 30, 2026, a 41.9% increase from the $3.7 million loss recorded in the same period of the previous year. For the first half of 2026, the company’s net loss was $8.1 million, up 11.9% from $7.3 million in the first half of 2025. The increase in losses was primarily attributed to a significant rise in research and development expenses, which surged by 71.5% to $3.7 million for the second quarter and by 70.9% to $6.6 million for the first half of the year, reflecting ongoing clinical trials and regulatory activities related to its lead product candidate, PAS-004.

Total operating expenses for the second quarter of 2026 reached $5.7 million, a 49.9% increase compared to $3.8 million in the same quarter of 2025. General and administrative expenses also rose, totaling $2.0 million for the second quarter, a 22.0% increase from $1.7 million in the prior year. The company attributed these increases to higher insurance costs, stock-based compensation, and other operational expenses. Despite the increase in expenses, Pasithea reported a substantial rise in other income, which amounted to $439,430 for the second quarter, compared to $94,742 in the same period last year, largely due to increased interest income.

As of June 30, 2026, Pasithea's total assets were approximately $51.7 million, down from $60.2 million at the end of 2025. The decrease was primarily due to a reduction in cash and cash equivalents, which fell to $45.7 million from $55.2 million. The company’s working capital also decreased to $46.4 million, down from $51.5 million at the end of the previous fiscal year. The decline in cash reserves was attributed to cash used in operations, which totaled $9.5 million for the first half of 2026, compared to $6.9 million in the same period of 2025.

In terms of strategic developments, Pasithea is advancing its clinical trials for PAS-004, a MEK inhibitor aimed at treating neurocutaneous manifestations of neurofibromatosis type 1 (NF1). The company initiated a Phase 1/1b trial in May 2025 and is conducting trials in multiple countries, including the United States, Australia, and South Korea. Additionally, the company has made organizational changes, including the adoption of a new stock incentive plan, which allows for the issuance of stock options and other equity awards to employees and board members.

Looking ahead, Pasithea anticipates continued increases in research and development expenses as it progresses through clinical trials and seeks regulatory approvals for its product candidates. The company remains dependent on raising additional capital through equity or debt financing to support its ongoing operations and development plans. Management believes that its current cash reserves will be sufficient to meet operational needs for at least the next twelve months, but acknowledges the need for significant additional funding to sustain its growth and development initiatives.